Non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R). MC4R activation in the medial preoptic area drives sexual desire centrally.
Reference facts
- Also known as
- Bremelanotide, Vyleesi
- Category
- Sexual Health & MSH
- Mechanism of action
- Non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R). MC4R activation in the medial preoptic area drives sexual desire centrally.
- Targets
- MC4R, MC3R, MC1R
- Indications under research or approved
- Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women
- Regulatory status (reference entry)
- FDA-approved (2019)
- Half-life
- ~2.7 hours (subcutaneous)
- Sequence notes
- Cyclic heptapeptide Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH derived from α-MSH.
- Molecular weight (Da)
- 1025
- Originator / sponsor
- AMAG / Palatin Technologies
- First reported
- 2003
Primary References
Explore research articles about PT-141
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.